From February 2021 to November 2021, the COVID-19 Vaccine Independent Safety Monitoring Board (the Board) met to review and discuss safety data for the Pfizer COVID-19 vaccine.
The Board has now published an interim report about its findings. The key findings have previously been publicly reported. During this period more than 7 million doses were administered.
Almost 90% of the eligible population (12 years and older) had received two doses of the vaccine. Given the large proportion of the population being vaccinated in a relatively short period of time, it is understandable that there were a number of adverse events reported following vaccination.
A number of events can also be expected to occur coincidentally in the period following vaccination. Of the reported adverse events, less than 5% are classified as serious.